Clinical Trial

Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07263906
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Enrollment 48 participants
Start Date 2025-12-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-04